1. Home
  2. HIT vs THAR Comparison

HIT vs THAR Comparison

Compare HIT & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Health In Tech Inc.

HIT

Health In Tech Inc.

HOLD

Current Price

$1.38

Market Cap

69.4M

Sector

Finance

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$2.37

Market Cap

82.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIT
THAR
Founded
1964
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.4M
82.7M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
HIT
THAR
Price
$1.38
$2.37
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
624.5K
340.9K
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$30,723,490.00
N/A
Revenue This Year
$70.02
N/A
Revenue Next Year
$44.08
N/A
P/E Ratio
$64.30
N/A
Revenue Growth
55.15
N/A
52 Week Low
$0.51
$0.95
52 Week High
$7.59
$9.08

Technical Indicators

Market Signals
Indicator
HIT
THAR
Relative Strength Index (RSI) 44.38 42.90
Support Level $1.03 $2.20
Resistance Level $1.46 $2.57
Average True Range (ATR) 0.17 0.17
MACD 0.08 0.00
Stochastic Oscillator 61.40 30.91

Price Performance

Historical Comparison
HIT
THAR

About HIT Health In Tech Inc.

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: